Summary of Significant Accounting Policies (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
Feb. 21, 2017 |
Sep. 30, 2017 |
Dec. 31, 2016 |
|
| Money Market Funds Fair Value | $ 750,946 | $ 1,500,882 | |
| Contingent Consideration Funds Fair Value | 1,210,000 | $ 1,210,000 | |
| Proceeds From Upfront Payment | $ 4,000,000 | ||
| New Valeant Agreement [Member] | |||
| Revenue Recognition, Milestone Method, Description | the Company is eligible to receive milestone payments totaling up to approximately $99.0 million, upon and subject to the achievement of certain specified developmental and commercial progress of the EGP-437 Product for the New Field. | ||
| Proceeds From Upfront Payment | $ 4,000,000 | 1,428,000 | |
| Jade Therapeutics, Inc [Member] | |||
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 3,912,314 |
| X | ||||||||||
- Definition These lines are represents the fair value of fund for contingent consideration. No definition available.
|
| X | ||||||||||
- Definition These lines are represents the fair value of fund for money market. No definition available.
|
| X | ||||||||||
- Definition This element represents the amount of cash inflow for upfront payment. No definition available.
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition A description of the overall arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|